

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 14 JANUARY 2022**

The board of directors of Shenzhen Neptunus Interlong Bio-technique Company Limited (the **“Company”**) hereby announces that the extraordinary general meeting (the **“EGM”**) was held on 14 January 2022 during which the proposed resolution set out in the notice of the EGM of the Company dated 17 December 2021 (the **“Notice”**) in relation to the approval, confirmation and ratification of the form and substance of the Healthcare Food and Food Purchase Framework Agreement (the **“2021 Healthcare Food and Food Purchase Framework Agreement”**) dated 6 December 2021 and entered into between the Company and Neptunus Group and all transactions contemplated thereunder and all related issues; and the approval, confirmation and ratification of the form and substance of the Distribution Agreement (the **“2021 Distribution Agreement”**) dated 6 December 2021 and entered into between Neptunus Changjian and Neptunus Pharmaceutical and all transactions contemplated thereunder and all related issues was duly passed by way of poll.

Reference is made to the Notice and the circular dated 30 December 2021 of the Company (the **“Circular”**). Unless otherwise defined, terms used herein shall have the same meaning as defined in the Circular.

The EGM of the Company was duly held at 10:00 a.m. on Friday, 14 January 2022 at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, the People's Republic of China (the **“PRC”**).

As at the date of the EGM, the total number of shares of the Company in issue was 1,678,000,000 shares (nominal value of RMB0.10 per share), of which 1,252,000,000 shares were domestic shares and 426,000,000 shares were H shares. Amongst all the shareholders, Neptunus Bio-engineering and its associate, Shenzhen Neptunus Oriental Investment Company Limited* (**“Neptunus Oriental”**), collectively hold 1,233,464,500 domestic shares (approximately 73.51% of the total issued shares) of the Company. As stated in the Circular, Neptunus Bio-engineering and its associate are required to abstain from voting at the EGM on the resolution to approve the 2021 Healthcare Food and Food Purchase Framework Agreement and the 2021 Distribution Agreement and all transactions contemplated thereunder and all related issues (the **“Resolution”**) due to their interests in the transactions. Accordingly, the total number of shares entitling the shareholders to attend and vote for or against the Resolution at the EGM was 444,535,500 shares. The board of directors of the Company confirms that Neptunus Bio-engineering and its associate, Neptunus Oriental, did abstain from voting on the Resolution in the EGM. Save as disclosed above, no shareholder of the Company was required under the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the **“GEM Listing Rules”**) to abstain from voting on the Resolution at the EGM.

There were no shares entitling the shareholder to attend and abstain from voting in favour of the Resolution at the EGM as set out in Rule 17.47A of the GEM Listing Rules.

Save as disclosed above, none of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on the Resolution at the EGM.

The Company's H Share Registrar and Transfer Office in Hong Kong, Tricor Investor Services Limited, was appointed and acted as the scrutineer for vote-taking at the EGM.

RESULTS OF EGM

The EGM was held at 10:00 a.m. on Friday, 14 January 2022 at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, the PRC. The proposed ordinary Resolution as set out in the Notice was duly passed by way of poll. The poll results are as follows:

Ordinary Resolution		No. of shares represented by votes cast (percentage of total number of shares represented by votes cast)	
		For	Against
As more than half (1/2) of the votes from the shareholders who attended and voted at the EGM were cast in favour of the following Resolution, the Resolution was duly passed as ordinary resolution:			
1.	<p>THAT</p> <p>(a) the form and substance of the healthcare food and food purchase framework agreement (the “2021 Healthcare Food and Food Purchase Framework Agreement”) dated 6 December 2021 entered into between the Company and 深圳海王集團股份有限公司 (Shenzhen Neptunus Group Company Limited*) (“Neptunus Group”) relating to the purchase of certain food and healthcare food products by the Company from Neptunus Group and its subsidiaries (excluding the Group) or any one of them, for them to distribute within the PRC (a copy of the 2021 Healthcare Food and Food Purchase Framework Agreement has been produced to the meeting and marked “A” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;</p> <p>(b) the form and substance of the distribution agreement (the “2021 Distribution Agreement”) dated 6 December 2021 entered into between 深圳海王長健醫藥有限公司 (Shenzhen Neptunus Changjian Pharmaceutical Company Limited*) (“Neptunus Changjian”), a wholly-owned subsidiary of the Company, and 深圳海王藥業有限公司 (Shenzhen Neptunus Pharmaceutical Company Limited*) (“Neptunus Pharmaceutical”), a wholly-owned subsidiary of Neptunus Group, relating to the purchase of pharmaceutical products by Neptunus Changjian from Neptunus Pharmaceutical for them to distribute in the PRC (a copy of the 2021 Distribution Agreement has been produced to the meeting and marked “B” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;</p>	4,311,000 (100%)	Nil (–%)

Ordinary Resolution		No. of shares represented by votes cast (percentage of total number of shares represented by votes cast)	
		For	Against
	<p>(c) the proposed purchase caps under the 2021 Healthcare Food and Food Purchase Framework Agreement for each of the years ending 31 December 2022, 2023 and 2024 be and are hereby confirmed and approved;</p> <p>(d) the proposed purchase caps under the 2021 Distribution Agreement for each of the years ending 31 December 2022, 2023 and 2024 be and are hereby confirmed and approved; and</p> <p>(e) any one director of the Company (the “Director”) be and is hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Directors may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2021 Healthcare Food and Food Purchase Framework Agreement, the 2021 Distribution Agreement, or any transactions contemplated thereunder.</p>		

All Directors of the Company attended the EGM.

By Order of the Board
**Shenzhen Neptunus Interlong Bio-technique
Company Limited***
Zhang Feng
Chairman

Shenzhen, the PRC, 14 January 2022

As at the date of this announcement, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Xu Yan He; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.

* For identification purpose only